Clin2
NCT05093153Possibly a fitRecruiting

Registry for adults with IgM blood protein conditions

Waldenstrom Macroglobulinemia

Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.

This study is a registry that collects information about adults with certain IgM-related blood conditions. It may help doctors better understand these illnesses and improve future care.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
1,000 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You are 18 years or older.
  • You have a confirmed diagnosis of an IgM monoclonal (M) protein condition within the last 30 years.
  • Your diagnosis is one of these: IgM monoclonal gammopathy of uncertain significance (MGUS)
  • or asymptomatic Waldenström’s macroglobulinemia (no symptoms)
  • or symptomatic Waldenström’s macroglobulinemia (symptoms).
  • You do not have a different type of lymphoproliferative (lymph) disease.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT00923507Recruiting
Study of blood cancers’ natural course and next treatment needs

This study follows people with certain slow-growing blood cancers (CLL/SLL, LPL/WM, and related conditions) to understand how they progress and what leads to needing treatment. It may help doctors predict changes over time and plan care more effectively.

Bethesda, Maryland
NCT04893564Recruiting
Testing blood DNA after 6 months of Waldenström treatment

This study looks at a blood test called circulating tumor DNA, measured after 6 months of treatment, to see how well it predicts outcomes in people with Waldenström macroglobulinemia. It may help doctors better judge who is responding and who may need treatment adjustments earlier.

Amiens
NCT04898647Recruiting
Study of blood thickness in Waldenström’s disease

This study looks at “hyperviscosity,” meaning very thick blood, in people with Waldenström macroglobulinemia (WM). Your results may help doctors better understand who needs treatment and what tests should be used, even if thick blood is not found.

Amiens
NCT07231952Recruiting· Phase 2
Pirtobrutinib, venetoclax, and rituximab for Waldenstrom's macroglobulinemia

This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and rituximab) for people newly diagnosed with Waldenstrom's macroglobulinemia who have not had treatment before and need therapy for their symptoms.

Boston, Massachusetts
NCT04702932Not yet recruiting
Study blood sample features in certain fever-related blood diseases

This study looks at genetic and other traits of tumor/blood cells in adults with specific blood conditions who have fevers with unclear cause plus symptoms like rash or joint pain. The goal is to better understand what drives these “hyperinflammatory” reactions and how to tell them apart from other illnesses.

Paris
NCT02269592Recruiting
Study blood marker changes in early, symptom-free blood cancers

This study follows people with early, “precursor” blood conditions to learn what changes in their blood or bone marrow signal progression. It may help doctors better predict outcomes and understand why some people develop symptom-causing cancer.

Boston, Massachusetts

Hear when a new Waldenstrom Macroglobulinemia trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.